Research Article

CSF-Targeted Proteomics Indicate Amyloid-Beta Ratios in Patients with Alzheimer’s Dementia Spectrum

Table 4

Linear regression between cognitive assessments and targeted proteomics.

CNMCIAD
squareBeta coefficient value squareBeta coefficient value squareBeta coefficient value

CDR
IASNTQSR0.0140.0950.1970.0290.1700.0020.0040.0130.898
VAELEDEK0.007-0.0330.6290.017-0.1220.0230.013-0.0950.321
VVSSIEQK0.0060.0120.8670.0190.1290.0160.0240.1420.141
GDSVVYGLR0.0130.0870.1990.0070.0570.2740.0060.0420.660
EPVAGDAVPGPK0.0080.0460.4950.006-0.0510.3330.011-0.0840.385
QETLPSK0.0150.0930.1680.0080.0680.1900.006-0.0410.676
ADAS-11
IASNTQSR0.145-0.0910.1830.0930.1420.0070.0170.1150.271
VAELEDEK0.160-0.1480.0180.097-0.1560.0020.013-0.0840.383
VVSSIEQK0.146-0.0930.1570.1060.184<0.0010.0900.2940.002
GDSVVYGLR0.145-0.0850.1790.0760.0350.4810.0130.0840.379
EPVAGDAVPGPK0.162-0.1540.0140.083-0.0940.0640.014-0.0920.345
QETLPSK0.143-0.0660.2960.0790.0690.1650.0090.0580.549
ADAS-13
IASNTQSR0.177-0.0820.2210.1290.1760.0010.0190.1450.166
VAELEDEK0.195-0.1560.0110.126-0.1650.0010.004-0.0550.564
VVSSIEQK0.172-0.0370.5650.1490.238<0.0010.0760.2780.004
GDSVVYGLR0.175-0.0640.2980.1060.0690.1610.0080.0850.375
EPVAGDAVPGPK0.192-0.1460.0170.108-0.0860.0830.005-0.0660.496
QETLPSK0.174-0.0570.3600.1090.0920.0600.0060.0700.472
MMSE
IASNTQSR0.034-0.1410.0530.065-0.1020.0530.0080.0000.998
VAELEDEK0.018-0.0210.7570.0590.0630.2260.0230.1220.202
VVSSIEQK0.018-0.0170.8070.078-0.1570.0020.023-0.1260.192
GDSVVYGLR0.0260.0930.1650.066-0.1020.0430.0100.0490.606
EPVAGDAVPGPK0.0170.0050.9460.055-0.0120.8170.0130.0720.459
QETLPSK0.0220.0650.3330.071-0.1270.0120.0100.0420.662

CN: cognitively normal; MCI: mild cognitive impairment; AD: Alzheimer’s disease. values < 0.05 are in bold.